BFM
PTGX icon

Boothbay Fund Management’s Protagonist Therapeutics PTGX Stock Holding History

Boothbay Fund Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,188
Closed -$846K – 1703
2024
Q4 		$779K Buy
+20,188
New +$880K 0.02% 715
2024
Q1 		– Sell
-80,607
Closed -$1.85M – 1864
2023
Q4 		$1.85M Buy
+80,607
New +$1.41M 0.05% 524
2022
Q3 		– Sell
-57,923
Closed -$458K – 2536
2022
Q2 		$458K Sell
57,923
-98,718
-63% -$1.19M 0.01% 1224
2022
Q1 		$3.71M Buy
+156,641
New +$4.41M 0.09% 308
2020
Q2 		– Sell
-23,039
Closed -$163K – 1085
2020
Q1 		$163K Buy
23,039
+10,146
+79% +$76K 0.01% 684
2019
Q4 		$91K Sell
12,893
-36,079
-74% -$358K 0.01% 766
2019
Q3 		$588K Sell
48,972
-56,993
-54% -$718K 0.05% 425
2019
Q2 		$1.28M Buy
+105,965
New +$1.17M 0.12% 218
2019
Q1 		– Sell
-19,917
Closed -$134K – 855
2018
Q4 		$134K Buy
+19,917
New +$158K 0.02% 527

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's PTGX Position: Q1 2025 in Review

Boothbay Fund Management sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 20,188 shares — an estimated $846K sold.

Boothbay Fund Management first reported a position in PTGX in Q4 2018 and held it in 9 quarters. The position peaked at $3.71M in Q1 2022. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Boothbay Fund Management reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 20,188 Protagonist Therapeutics shares in Q1 2025, an estimated $846K.
  • Boothbay Fund Management first reported a position in Protagonist Therapeutics in Q4 2018 and held it in 9 quarters.
  • Boothbay Fund Management's Protagonist Therapeutics position peaked at $3.71M in Q1 2022.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.